OBJECTIVE: To evaluate the impact of distance from residence to treatment center on disease characteristics and recurrence of cervical cancer. MATERIALS AND METHODS: A single-institution retrospective chart review of patients treated for cervical cancer during 2006-2011 was performed. Demographic, socioeconomic, and clinicopathologic characteristics were recorded. Distance traveled from home to treatment facility was calculated and categorized. Recurrence and follow-up data were extracted; progression-free survival and overall survival were calculated. SAS version 9.2 was used for statistical analysis. RESULTS: Two hundred nineteen patients met the study criteria; 75% were Caucasian. Forty-nine percent used tobacco. Twenty-five percent had stage III/IV disease. Insurance type was 46% private, 25% Medicaid, 20% Medicare, and 9% uninsured. Distance between residence and hospital was less than 15 miles (29%), 15 to 30 miles (21%), 30 to 50 miles (17%), and more than 50 miles (33%). Median follow-up period was 23 months (range, 1-65). Caucasians were more likely to travel more than 30 miles to a treatment center (P = 0.018) Non-Caucasians were less likely to have private insurance (P = 0.0005) and more likely to recur (P = 0.0045). Recurrence was highest (50%) in African Americans. Travel of more than 30 miles was not associated with age, stage, histology, tobacco abuse, employment, clinical trial enrollment, primary chemoradiation for stage IB disease, or delayed radiation. Travel of more than 30 miles was associated with government insurance (P = 0.029) and a trend toward unemployment (P = 0.059). Four-year progression-free survival (53% vs 52%; P = 0.992) and overall survival (57% vs 62%; P = 0.73) were similar between less than or more than 30-mile travel. CONCLUSIONS: Fifty percent of the patients reside more than 30 miles from treating hospital. Despite farther travel, stage of disease, clinical trial enrollment, treatment type, radiation completion, and recurrence rates were similar among patients with cervical cancer. Non-Caucasians are less likely to travel more than 30 miles.
OBJECTIVE: To evaluate the impact of distance from residence to treatment center on disease characteristics and recurrence of cervical cancer. MATERIALS AND METHODS: A single-institution retrospective chart review of patients treated for cervical cancer during 2006-2011 was performed. Demographic, socioeconomic, and clinicopathologic characteristics were recorded. Distance traveled from home to treatment facility was calculated and categorized. Recurrence and follow-up data were extracted; progression-free survival and overall survival were calculated. SAS version 9.2 was used for statistical analysis. RESULTS: Two hundred nineteen patients met the study criteria; 75% were Caucasian. Forty-nine percent used tobacco. Twenty-five percent had stage III/IV disease. Insurance type was 46% private, 25% Medicaid, 20% Medicare, and 9% uninsured. Distance between residence and hospital was less than 15 miles (29%), 15 to 30 miles (21%), 30 to 50 miles (17%), and more than 50 miles (33%). Median follow-up period was 23 months (range, 1-65). Caucasians were more likely to travel more than 30 miles to a treatment center (P = 0.018) Non-Caucasians were less likely to have private insurance (P = 0.0005) and more likely to recur (P = 0.0045). Recurrence was highest (50%) in African Americans. Travel of more than 30 miles was not associated with age, stage, histology, tobacco abuse, employment, clinical trial enrollment, primary chemoradiation for stage IB disease, or delayed radiation. Travel of more than 30 miles was associated with government insurance (P = 0.029) and a trend toward unemployment (P = 0.059). Four-year progression-free survival (53% vs 52%; P = 0.992) and overall survival (57% vs 62%; P = 0.73) were similar between less than or more than 30-mile travel. CONCLUSIONS: Fifty percent of the patients reside more than 30 miles from treating hospital. Despite farther travel, stage of disease, clinical trial enrollment, treatment type, radiation completion, and recurrence rates were similar among patients with cervical cancer. Non-Caucasians are less likely to travel more than 30 miles.
Authors: T Clark Powell; Sarah E Dilley; Sejong Bae; J Michael Straughn; Kenneth H Kim; Charles A Leath Journal: J Low Genit Tract Dis Date: 2018-10 Impact factor: 1.925
Authors: Christian Lopez Ramos; Michael G Brandel; Jeffrey A Steinberg; Arvin R Wali; Robert C Rennert; David R Santiago-Dieppa; Reith R Sarkar; J Scott Pannell; James D Murphy; Alexander A Khalessi Journal: J Neurooncol Date: 2018-11-20 Impact factor: 4.130
Authors: Yolanda J McDonald; Daniel W Goldberg; Isabel C Scarinci; Philip E Castle; Jack Cuzick; Michael Robertson; Cosette M Wheeler Journal: J Rural Health Date: 2016-08-24 Impact factor: 4.333
Authors: David A Barrington; Sarah E Dilley; Emily E Landers; Eric D Thomas; Jonathon D Boone; J Michael Straughn; Gerald McGwin; Charles A Leath Journal: Gynecol Oncol Date: 2016-10-06 Impact factor: 5.482
Authors: Dragomir Svetozarov Stoyanov; Nikolay Vladimirov Conev; Ivan Shterev Donev; Ivan Dimitrov Tonev; Teodorika Vitalinova Panayotova; Eleonora Georgieva Dimitrova-Gospodinova Journal: Support Care Cancer Date: 2022-03-15 Impact factor: 3.603
Authors: Jennifer Alford-Teaster; Jane M Lange; Rebecca A Hubbard; Christoph I Lee; Jennifer S Haas; Xun Shi; Heather A Carlos; Louise Henderson; Deirdre Hill; Anna N A Tosteson; Tracy Onega Journal: Int J Health Geogr Date: 2016-02-18 Impact factor: 3.918
Authors: Jonah Musa; Chad J Achenbach; Linda C O'Dwyer; Charlesnika T Evans; Megan McHugh; Lifang Hou; Melissa A Simon; Robert L Murphy; Neil Jordan Journal: PLoS One Date: 2017-09-05 Impact factor: 3.240